AU2017268039A1 - Treatment of pain - Google Patents

Treatment of pain Download PDF

Info

Publication number
AU2017268039A1
AU2017268039A1 AU2017268039A AU2017268039A AU2017268039A1 AU 2017268039 A1 AU2017268039 A1 AU 2017268039A1 AU 2017268039 A AU2017268039 A AU 2017268039A AU 2017268039 A AU2017268039 A AU 2017268039A AU 2017268039 A1 AU2017268039 A1 AU 2017268039A1
Authority
AU
Australia
Prior art keywords
compound
signaling
endosomal
par
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017268039A
Other languages
English (en)
Inventor
Nigel BUNNETT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901912A external-priority patent/AU2016901912A0/en
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2017268039A1 publication Critical patent/AU2017268039A1/en
Priority to AU2023201732A priority Critical patent/AU2023201732A1/en
Priority to AU2025202933A priority patent/AU2025202933A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017268039A 2016-05-20 2017-05-19 Treatment of pain Abandoned AU2017268039A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023201732A AU2023201732A1 (en) 2016-05-20 2023-03-20 Treatment of pain
AU2025202933A AU2025202933A1 (en) 2016-05-20 2025-04-28 Treatment of Pain

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016901912 2016-05-20
AU2016901912A AU2016901912A0 (en) 2016-05-20 Treatment of Pain
PCT/AU2017/050469 WO2017197463A1 (en) 2016-05-20 2017-05-19 Treatment of pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023201732A Division AU2023201732A1 (en) 2016-05-20 2023-03-20 Treatment of pain

Publications (1)

Publication Number Publication Date
AU2017268039A1 true AU2017268039A1 (en) 2018-12-06

Family

ID=60324618

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017268039A Abandoned AU2017268039A1 (en) 2016-05-20 2017-05-19 Treatment of pain
AU2023201732A Abandoned AU2023201732A1 (en) 2016-05-20 2023-03-20 Treatment of pain
AU2025202933A Pending AU2025202933A1 (en) 2016-05-20 2025-04-28 Treatment of Pain

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023201732A Abandoned AU2023201732A1 (en) 2016-05-20 2023-03-20 Treatment of pain
AU2025202933A Pending AU2025202933A1 (en) 2016-05-20 2025-04-28 Treatment of Pain

Country Status (10)

Country Link
US (1) US20190298743A1 (enExample)
EP (1) EP3458062A4 (enExample)
JP (3) JP2019516734A (enExample)
CN (1) CN109152777A (enExample)
AU (3) AU2017268039A1 (enExample)
CA (1) CA3024719A1 (enExample)
EA (1) EA201892672A1 (enExample)
MX (2) MX395658B (enExample)
NZ (2) NZ788380A (enExample)
WO (1) WO2017197463A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086458A1 (en) * 2017-12-20 2019-06-27 Takeda Pharmaceutical Company Limited Inhibitors of protease activated receptor-2
US20240066027A1 (en) 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
WO2023233033A1 (en) 2022-06-03 2023-12-07 Domain Therapeutics Novel par-2 inhibitors
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US7541156B1 (en) * 2000-03-01 2009-06-02 Pasricha Pankaj J Method of identifying antinociceptive compounds using protease activated receptor-2
GB2426517A (en) * 2003-11-21 2006-11-29 Univ Newcastle Res Ass Methods and agents for inhibiting dynamin-dependent endocytosis
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
CA2562266A1 (en) * 2004-04-08 2005-10-20 Jadolabs Gmbh Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
JP4896870B2 (ja) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
WO2009034464A2 (en) * 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
WO2013010218A1 (en) * 2011-07-15 2013-01-24 Freie Universität Berlin Inhibition of clathrin
TW201602109A (zh) * 2013-09-25 2016-01-16 維泰克斯製藥公司 作為ｐａｒ－２訊息傳遞路徑之抑制劑之咪唑并嗒
CN115531553A (zh) * 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
AT518095B1 (de) * 2015-12-30 2018-01-15 Univ Wien Tech Verfahren zur Herstellung von ionischen Flüssigkeiten auf Basis des Bistriflimid-Anions
CA3086458A1 (en) * 2017-12-20 2019-06-27 Takeda Pharmaceutical Company Limited Inhibitors of protease activated receptor-2

Also Published As

Publication number Publication date
MX395658B (es) 2025-03-26
JP2024073450A (ja) 2024-05-29
EP3458062A1 (en) 2019-03-27
AU2023201732A1 (en) 2023-04-20
CA3024719A1 (en) 2017-11-23
JP2022061998A (ja) 2022-04-19
JP2019516734A (ja) 2019-06-20
AU2025202933A1 (en) 2025-05-15
JP7441246B2 (ja) 2024-02-29
NZ748579A (en) 2025-07-25
CN109152777A (zh) 2019-01-04
EP3458062A4 (en) 2020-01-15
EA201892672A1 (ru) 2019-04-30
MX2022011564A (es) 2023-06-15
MX2018014135A (es) 2019-06-17
NZ788380A (en) 2025-07-25
WO2017197463A1 (en) 2017-11-23
US20190298743A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
JP7441246B2 (ja) 疼痛の治療
US20250235544A1 (en) Tripartite Modulators of Endosomal G Protein-Coupled Receptors
US20070196395A1 (en) Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US20170275249A1 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
WO2018053373A1 (en) Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
MXPA03011331A (es) Tratamiento del dolor mediante el direccionamiento de canales se abren por un nucleotido ciclico, activado mediante hiperpolarizacion.
US20030232815A1 (en) Non-peptidic cyclophilin binding compounds and their use
US20200383985A1 (en) Inhibitors of Protease Activated Receptor-2
EP1545287B1 (en) Vasoregulating compounds and methods of their use
EP3373947B1 (en) Compounds and methods for treating pain
BR112018012425B1 (pt) Composto tripartido, e, composição farmacêutica
US20200206299A1 (en) Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain
WO2009038289A2 (en) Pharmaceutical compositions for preventing or treating fibrosis

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted